Find out what to include in a cash flow statement, as well as its limitations and how cash flow is calculated.

The stock jumped 280% in 2025, and that could be the start of more upside. Analysts are steadily raising price targets on this drone technology purveyor. A broad customer base could support share ...

Cybin Inc. is rated Hold, with 2026 pivotal clinical milestones expected for CYB003 and CYB004 and a discounted valuation profile. CYBN's $248M pro forma cash position provides a 21–22 month runway, ...

Spyre Therapeutics offers a de-risked clinical pipeline and a robust cash runway extending into H2 2028, mitigating near-term financing risk. SYRE’s portfolio targets validated mechanisms—alpha-4 beta ...